eli lilly and co lly has agreed to acquire dice therapeutics inc dice a biopharmaceutical company that leverages its proprietary delscape technology platform to develop oral therapeutic candidates for immunology indications lilly will commence a tender offer to acquire all outstanding shares of dice for a purchase price of 48 per share in cash an aggregate of approximately 24 billion kevin judice ceo of dice therapeutics added were eager to see our pipeline including our oral il17 inhibitors dc806 and dc853 benefit from lillys resources and global reach the purchase price payable at closing represents a premium of approximately 40 to the 30day volumeweighted average trading price of dices common stock ended on june 16 2023 the transaction is expected to close in the third quarter of 2023 the first patient has been dosed in a doseranging phase 2b trial of dices lead oral il17 inhibitor dc806 for moderatetosevere psoriasis continued enrollment of participants in dices phase 1 clinical trial of dc853 a second oral il17 antagonist in healthy volunteers topline data are expected in the second half of 2023 price action dice shares are up 381 at 4675 and lly shares are up 107 at 45248 on the last check tuesday